Why BioPhorum’s trace element approach will save you time, money and wasted batches

1 June 2021
Drug Substance

Drug products can be heavily impacted when raw materials cause variability – anecdotal evidence suggests that batches worth millions of dollars are sometimes discarded due to trace elements coming through the supply chain.

Not only does this increase costs and significantly impact production scheduling, but it could delay the manufacture of drugs that may, ultimately, impact patients.

Yet, despite these industry-wide issues, there is no harmonization or best practice and some companies have even optimized their methods for certain metals.

This galvanized BioPhorum to bring together a team of experts to investigate the reasons why variation happens and develop an industry-agreed solution.

The result is Media and hydrolysates, which gives you a strategy for a method development and outlines the process to detect trace elements in chemically defined media and soy hydrolysates.

“This has been an open secret in our industry for many years,” said Bala Ramanathan, Associate Director at Janssen and lead author of the paper. “I don’t think there’s a company, especially on the biopharmaceutical side, which has not been impacted by trace elements in upstream bioprocessing.”

groundbreaking collaboration

The idea was formed at a BioPhorum meeting in Switzerland in 2019, where there was confusion around trace element characterization. Members wanted to know what methodologies other companies were using – without revealing their own.

This prompted the BioPhorum Raw Materials subteam to carry out benchmarking and design a test for trace elements using five samples – three commercial DMEM (Dulbecco’s Modified Eagle Medium) and two hydrolysis – and distributed them globally to 16 participating companies.

This groundbreaking BioPhorum collaboration shared blinded data and compared analytical methods between biopharmaceutical and media manufacturers. Anonymity was critical for companies to take part. The paper discusses the issues around trace elements and uses graphs to show the results of the project’s findings and the variability in identifying trace elements.

It looks at the fundamental issues you should consider when developing your method. Some of these are short-term, e.g., how much time, resources, and labor are available? And do you use contract labs with enough technological know-how? Others have a longer-term impact, e.g., if an issue is identified, how will you stop it from happening again? And will you just look at high-risk components in your media?

It also considers current best practices, which metals should be targeted, using inductively coupled plasma mass spectrometry, and key technical issues such as sample preparation, acid selection, and thermal hot block or microwave degradation.

Industry-wide impact

The project was well received by US Pharmacopeia (USP), which has formed a Trace Metals Expert Panel to develop a new General Chapter to build on Chapter <233> for these applications. BioPhorum has also requested revisions to Chapter <233>, including changes to instrumentation, sample digestion, and polyatomic interference.

An updated Chapter means that anyone considering working with chemically defined media and soy hydrolysates can implement best practices and ensure they meet customer requirements. This builds on current guidance, which only focuses on small molecule products.

This is an excellent example of work to support the recent BioPhorum/USP letter of intent that signposted how the partnership will work together to advance scientific collaboration by harmonizing industry practices and incorporating these into pharmacopeial standards. “This kind of collaborative relationship is beneficial across the board,” said Aaron Mack, Senior Engineer at Biogen, “because it reduces costs, waste, testing and reduces time overall to better supply raw materials for all manufacturers.”

BioPhorum Raw Material Logo
BioPhorum’s strategic framework shines a light on raw material management
DNA pink background
Registering innovative raw materials using QbD principles: Protein A resins
Demand Planning Text
Supplier and raw material improvements using BioPhorum’s maturity assessment toolkit
Raw Materials Logo On Green Background
How to understand and mitigate the problem of trace element variation
Arrow On Colourful Background
Do you want to influence the future of long-range planning?

Advanced Therapy Medicinal Products

Advanced Therapy Medicinal Products support the quest for better and faster development of cell, gene and RNA therapies​ through connecting therapy developers, contract manufacturing, and testing organizations to gain an understanding and respond to the challenges faced by the advanced therapeutics industry.

Development Group

Development Group accelerates and improves the development process of biopharmaceutical medicines for the benefit of the patient. Replacing isolation with collaboration by providing a “safe” space where subject matter experts can work on sharing solutions and best practice on emerging industry trends, implementation of new technologies and common issues whilst ensuring their intellectual property and confidentiality is protected.

Drug Substance

Drug Substance advances excellence in drug substance manufacturing and testing, acting as an industry voice to accelerate technology adoption, implement post-approval change more rapidly and increase confidence in maintaining compliance.

Fill Finish

Fill Finish accelerates development and acceptance of sustainable world-class filling and packaging operations for drug product which meets the future needs of patients. Through innovative solutions resulting from the sharing of expertise, we can overcome common performance challenges and deliver on quality and regulatory compliance.

Information Technology

Information Technology accelerates digital maturity across the ​global pharmaceutical manufacturing industry.


BioPhorum Quality provides a dedicated, safe space for quality professionals from biomanufacturers and contract organizations to coalesce and enhance effective collaboration to address shared industry challenges.


Regulatory CMC brings leaders together who have a common goal – to improve access to medicines through innovation in the Regulatory ecosystem. It provides a dedicated space for strategic leadership and a coordinated industry voice, to move from divergence to convergence.

Supply Chain to Patient

Supply Chain to Patient transforms the performance of global pharmaceutical clinical and commercial outbound supply chains through industry collaboration by creating transparent patient-centric, resilient and agile E2E supply chains, that consistently deliver high-quality medicines ensuring an uninterrupted supply to patients.

Supply Partner

Supply Partner is a trusted advisory group and collaboration that is the engine for driving change across the global industry for all things relevant to the inbound supply chain. Addressing the challenges of complexity, resilience, cost, sustainability, and innovation.


Sustainability enables the industry’s transition to a low carbon, circular future – supporting members to improve patient health while respecting the planet. We activate multi-disciplinary teams drawn from our network to deliver environmental sustainability improvements across the value chain.

Technology Strategy

Technology Strategy acts as one voice of the industry to define strategy, accelerate technology transformation and support technology translation and adoption. With a purpose of enabling the future state of flexible, resilient, sustainable end-to-end biomanufacturing.

An industry perspective on understanding AAV capsid content variants
Needle On Yellow Background
An intercompany perspective on practical experiences of predicting, optimizing and analyzing high concentration biologic therapeutic formulations
The Drug Substance 2.0 Strategic Value Framework
Coloured dots on teal, next to vial
BioPhorum’s holistic approach to container closure integrity
Magnifying glass over a tablet all coloured blue
Digital Plant Maturity Model 3.0
Investigation Digital Workstreams
Peer to peer practical guidance on remote inspections and audits
The next step in building regulatory as a capability to enable strategic innovation across the BioPhorum community
BioPhorum roundals on sugical gloves
A visionary strategic framework for future patient-centric outbound biopharmaceutical supply chains
DNA and Earth on blue background
A vision for the biopharmaceutical industry’s inbound supply chain
Lightbulb And Icons On Colourful Background
BioPhorum environmental sustainability roadmap 2022
Technology Roadmap V 2.0
BioPhorum Technology Roadmapping roadmap vision 2.0


Documents including best practices, vision statements and peer reviewed papers to help you take value back to your business.


Discussing all aspects of the biopharmaceutical industry, from digitization and knowledge management to raw materials, supply chain, sustainability and more. Learn from the perspectives of those at the forefront of the industry.


BioPhorum Connect is our podcast series that keeps you up to date with the latest news and trends in the biopharmaceutical industry. From experienced professionals to thought leaders, these podcasts bring you the insights and perspectives of experts from around the world.


A variety of resources including design tools and user requirement specifications to help you improve and streamline your business processes.

Benchmarks and Surveys

Research conducted among the BioPhorum membership providing evidence to support change and identify best practice.

Browse all

Access a variety of free tools and papers and other resources designed to provide you with up-to-date information and insights to help you make informed decisions and maximize your success. Access our resources today and start making improving and streamlining your business processes.

Bioreactivity testing in single-use system biomanufacturing
Bioreactivity testing in single-use system biomanufacturing
Bioreactivity testing in single-use system biomanufacturing
Magnifying glass over a tablet all coloured blue
Digital Plant Maturity Model 3.0
Bioreactivity testing in single-use system biomanufacturing